Cagrilintide reconstitution calculator
Type in a vial size, the diluent volume you added, and a dose figure — the calculator below converts those three numbers into a concentration, a draw volume, and a syringe reading. It performs the same arithmetic as our tirzepatide and sermorelin calculators. What it cannot do, for cagrilintide specifically, is check that arithmetic against an FDA-approved product's own label, because no such label — or product — exists for cagrilintide on its own. Read why below before you use it.
Cagrilintide alone has no FDA filing — only its combination with semaglutide does
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. As a standalone drug it has never been filed with the FDA at all — Novo Nordisk's regulatory strategy for it is combination-only, and there is no NDA or BLA submission for cagrilintide on its own to check a vial against. What the company HAS filed is CagriSema, a fixed-dose weekly co-formulation of cagrilintide 2.4 mg with semaglutide 2.4 mg: Novo Nordisk submitted CagriSema's NDA to FDA on December 18, 2025, and has said it anticipates a decision by late 2026 — a real, pending application, but not yet an approval, and not one covering cagrilintide by itself.
Do not read "CagriSema is under FDA review" as "cagrilintide is approved," or close to it. In REDEFINE-1, the Phase 3 trial behind that filing, semaglutide alone produced 16.1% weight loss and cagrilintide alone produced 11.8% — cagrilintide's own monotherapy arm performed worse than semaglutide's, while the CagriSema combination reached 22.7%. The filing's case rests on the two drugs together, not on cagrilintide's standalone result. A direct check of DailyMed, the National Library of Medicine's official archive of FDA-approved drug labeling, returns zero results for both "cagrilintide" and "CagriSema" — no approved label exists for either, filed application or not. Cagrilintide is also not one of the peptides FDA's Pharmacy Compounding Advisory Committee reviewed for its 503A bulk-substances list in July 2026; its regulatory story runs entirely through Novo Nordisk's NDA pipeline, not that track.
What the tool below actually does is narrower than that context might suggest: it takes the vial size, diluent volume, and dose you type in and returns the concentration and draw volume that arithmetic implies — nothing more. It cannot confirm that a particular vial is what its label claims, that the dose you enter is appropriate for you, or that the product you drew that number from came from a legitimate source. A correct-looking syringe reading is not evidence that any of those things are true.
Sources: DailyMed structured-product-label search for "cagrilintide" and "CagriSema" (zero results for both), an openFDA Drugs@FDA query for both terms (no matching applications), and Novo Nordisk's December 18, 2025 press release announcing the CagriSema NDA filing and REDEFINE-1 results, all independently checked 2026-08-02. View the DailyMed search · View the CagriSema NDA filing announcement.
Where to go next
- Compare against the compounds this calculator supports that do have an FDA-approved reference product, on the calculator hub.
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.